Decision Date:
February 2024


RED: Use in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase-1 R132 mutation who are not eligible to receive standard induction chemotherapy. (Decision date - Sep 2023)

RED: for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments - as per NICE TA948. NHSE commissioned (Decision date - February 2024)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app